Resource Summary Report

Generated by dkNET on Jul 31, 2026

ADNI - Alzheimer's Disease Neuroimaging Initiative

RRID:SCR_003007
Type: Tool

Proper Citation

ADNI - Alzheimer's Disease Neuroimaging Initiative (RRID:SCR_003007)

Resource Information

URL: http://adni-info.org/

Proper Citation: ADNI - Alzheimer's Disease Neuroimaging Initiative (RRID:SCR_003007)

Description: Database of the results of the ADNI study. ADNI is an initiative to develop biomarker-based methods to detect and track the progression of Alzheimer's disease (AD) that provides access to qualified scientists to their database of imaging, clinical, genomic, and biomarker data.

Abbreviations: ADNI

Synonyms: Alzheimers Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer's Disease Neuroimaging Initiative

Resource Type: service resource, data repository, data or information resource, database, storage service resource

Keywords: mri, alzheimer???s disease, cognitive assessment, neuroimaging, disease study, disease progression, biomarker, FASEB list

Related Condition: Alzheimer's disease, Mild Cognitive Impairment, Elderly control, Traumatic brain injury, Post-Traumatic Stress Disorder, Aging

Funding: NIA U01AG024904;
NIA P30AG010129;
NIA K01AG030514

Availability: Application required, Account required, This resource is available to the scientific community

Resource Name: ADNI - Alzheimer's Disease Neuroimaging Initiative

Resource ID: SCR_003007

Alternate IDs: SciRes_000144, nif-0000-00516

Alternate URLs: http://adni.loni.usc.edu/, http://www.nitrc.org/projects/adni/, http://www.adni3.org/

Old URLs: http://www.loni.ucla.edu/ADNI/

License: ADNI License

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260731T042644+0000

Ratings and Alerts

No rating or validation information has been found for ADNI - Alzheimer's Disease Neuroimaging Initiative.

No alerts have been found for ADNI - Alzheimer's Disease Neuroimaging Initiative.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 3850 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Boutin S, et al. (2026) Uncovering pathology, subjective cognitive complaints, and sex in early Alzheimer's disease. Journal of Alzheimer's disease : JAD, 109(1), 203.

Zhu Z, et al. (2026) Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(1), e71064.

Ferreira PCL, et al. (2026) Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Neurology, 106(1), e214441.

Li Y, et al. (2026) Shannon Entropy of Gray Matter Eigenmodes: A Novel Biomarker for Alzheimer's Disease and Heterogeneous MCI Trajectories. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(1), e11614.

Fonseca CS, et al. (2026) Spatial patterns of tau accumulation across the Alzheimer's disease spectrum. Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(1), e71076.

Mohanty R, et al. (2025) Distinct cerebrovascular pathways underlying Alzheimer's disease-related neurodegeneration. Acta neuropathologica, 150(1), 64.

Ioannou K, et al. (2025) Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study. Molecular psychiatry, 30(2), 587.

Toccaceli Blasi M, et al. (2025) Sex-specific clinical and neurobiological correlates of fatigue in older adults. GeroScience, 47(1), 1151.

Dao DP, et al. (2025) Longitudinal Alzheimer's Disease Progression Prediction With Modality Uncertainty and Optimization of Information Flow. IEEE journal of biomedical and health informatics, 29(1), 259.

Engvig A, et al. (2025) Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction. GeroScience, 47(2), 2099.

Khobragade PY, et al. (2025) Design and methodology of the harmonized diagnostic assessment of dementia for the longitudinal aging study in India: Wave 2. Journal of the American Geriatrics Society, 73(3), 685.

Zhao H, et al. (2025) Suppressing DUSP16 overexpression induced by ELK1 promotes neural progenitor cell differentiation in mouse models of Alzheimer's disease. Aging cell, 24(2), e14372.

Xie L, et al. (2025) A multi-cohort study of longitudinal and cross-sectional Alzheimer's disease biomarkers in cognitively unimpaired older adults. Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(2), e14492.

Xu X, et al. (2025) Deciphering novel mitochondrial signatures: multi-omics analysis uncovers cross-disease markers and oligodendrocyte pathways in Alzheimer's disease and glioblastoma. Frontiers in aging neuroscience, 17, 1536142.

Sim MA, et al. (2025) Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study. Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(2), e14577.

Wesenhagen KEJ, et al. (2025) Synaptic protein CSF levels relate to memory scores in individuals without dementia. Alzheimer's research & therapy, 17(1), 56.

Bellou E, et al. (2025) Benchmarking Alzheimer's disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies. Alzheimer's research & therapy, 17(1), 6.

Amjad U, et al. (2025) Context aware machine learning techniques for brain tumor classification and detection - A review. Heliyon, 11(2), e41835.

Plini ERG, et al. (2025) Meditation Linked to Enhanced MRI Signal Intensity in the Pineal Gland and Reduced Predicted Brain Age. Journal of pineal research, 77(2), e70033.

Hagos MT, et al. (2025) Reducing inference cost of Alzheimer's disease identification using an uncertainty-aware ensemble of uni-modal and multi-modal learners. Scientific reports, 15(1), 5521.